A pragmatic and cost-effective strategy of a combination therapy of interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 5, 2001, Pages 483-488

  Sagmeister, Markus ^a,b   Wong, John B ^b   Mullhaupt, Beat ^c   Renner, Eberhard L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Cost effectiveness; Costs; Hepatitis c; Interferon; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIFE EXPECTANCY; MALE; MONOTHERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

ADULT; ANTIVIRAL AGENTS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN; SWITZERLAND; TREATMENT OUTCOME;

EID: 0035012271     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/00042737-200105000-00004     Document Type: Article

References (32)

1. Esteban JI, Lopez-Talavera JC, Genesca J, Madoz P, Viladomiu L, Muniz E. et al. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus. Ann Intern Med 1991; 115: 443-449.
2. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL. et al. Long term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992; 327: 1906-1911.
3. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 1991; 14: 669-674.
4. Fattovich G, Giustina G, Degos F, Treolada F, Diodati G, Almasio P. et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.
5. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero ML. et al. Long-term follow-up of non-A, non-B (type C) post transfusion hepatitis. J Hepatol 1992; 16: 273-281.
6. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y. et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-675.
7. Di Bisceglie AM, Order SE, Klein JL, Waggoner JG, Sjogren MH, Kuo G. et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991; 86: 335-338.
8. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996; 24: 778-789.
9. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histology mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-865.
10. Dusheiko GM, Roberts JA. Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal. Hepatology 1995; 22: 1863-1873.
11. Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW. Cost-effectiveness of 6 and 12 months of interferon-alfa therapy for chronic hepatitis C. Ann Intern Med 1997; 127: 866-874.
12. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon α2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87.
13. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G. et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
14. McHutchison JG, Gordoni SC, Schiff ER, Shiffmann ML, Lee WM, Rustgi VK. et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
15. Younossi ZM, Singer E, McHutchison JG, Shermock KM. Cost effectiveness of interferon α-2b combined with ribavirin for the treatment of chronic hepatitis. Hepatology 1999; 30: 1318-1324.
16. Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastroenterol 2000; 95: 1525-1529.
17. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an ‘a la carte’ combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with hepatitis C? Hepatology 2000; 31: 211-218.
18. Sonnenberg FA, Pauker SG. Decision Maker 7.0. Boston: New England Medical Center 1999.
19. Wong JB, Bennett WB, Koff RS, Pauker SG. Pretreatment evaluation of hepatitis C: Risks, benefits and costs. JAMA 1998; 280: 2088-2093.
20. Sagmeister M, Renner EL, Müllhaupt B, Wong JB. Modeling of hepatitis C in Switzerland: prevalence, future epidemic and costs. Schweiz Med Wochenschr 2000; 121 (suppl): 9.
21. European Association for the Study of the Liver. Consensus statement, EASL International Consensus Conference on Hepatitis C, 26-28 February, 1999, Paris. J Hepatol 1999; 30: 956-961.
22. Schweizerische Expertengruppe fuer Virale Hepatitis (SEVHEP). Empfehlungen fuer die Therapie der chronischen Hepatitis C mit Interferon. Schweizerische Aerztezeitung 1996; 77: 1744-1745.
23. Swiss Association for the Study of the Liver (SASL), Schweizerische Expertengruppe fuer Virale Hepatitis (SEVHEP), Schweizerische Gesellschaft fuer Gastroenterologie und Hepatologie (SGGH), Fachgesellschaft der Schweizerischen Gastroenterologen (FAGAS): Empfehlungen zur Therapie der Hepatitis C. Unpublished paper 1999.
24. National Institutes of Health Consensus. Management of hepatitis C. Hepatology 1997; 26 (suppl): 1-156.
25. Verbindung der Schweizer Aerzte, Versicherer gemaess UVG, Militaerversicherung, Invalidenversicherung: Aerztetarif. Luzern 1998.
26. VESKA. VESKA Diagnosenstatistik 1996. Aarau 1997.
27. Arbeitsgruppe Schweizerisches Institut fuer Gesundheits- und Krankenhauswesen (SKI). Lebertransplantation in der Schweiz. Aarau 1989.
28. Bundesamt für Statistik. Statistisches Jahrbuch der Schweiz 1997. Zurich: Bundesamt für Statistik; 1998.
29. Read JL, Quinn RJ, Berwick DM, Fineberg HV, Weinstein MC. Preferences for health outcomes: Comparison of assessment methods. Med Decis Making 1984; 34: 559-569.
30. Cohen DJ, Breall JA, Ho KK, Kuntz RE, Goldman L, Baim DS. et al. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model. Circulation 1994; 89: 1859-1874.
31. Johannesson M, Jönnsson B, Kjekhus J, Olsson AG, Pedersen TR, Wedel H. et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-336.
32. Kim WR, Poterucha JJ, Dickson ER, Gross JB. Optimal treatment strategy for chronic hepatitis C in 1999. Gastroenterology 1999; 116: L220